These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2613104)

  • 1. [Antithrombotic effects of low molecular weight heparin (FR-860) in rabbits].
    Hamano S; Komatsu H; Ikeda S; Sakuragawa N
    Nihon Yakurigaku Zasshi; 1989 Oct; 94(4):237-42. PubMed ID: 2613104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of low molecular weight heparin (FR-860) on coagulative and fibrinolytic activities].
    Hamano S; Kinukawa M; Komatsu H; Ikeda S; Sakuragawa N
    Nihon Yakurigaku Zasshi; 1989 Oct; 94(4):243-9. PubMed ID: 2613105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effect of low molecular weight heparin on the hemodialysis model in dogs.
    Hamano S; Komatsu H; Ikeda S; Takahashi K; Oguma Y; Sakuragawa N
    Thromb Res; 1989 Aug; 55(4):439-49. PubMed ID: 2554525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of low molecular weight heparin (FR-860) on the experimental disseminated intravascular coagulation models].
    Hamano S; Kinukawa M; Komatsu H; Miyata H; Sakuragawa N
    Nihon Yakurigaku Zasshi; 1991 Jul; 98(1):53-62. PubMed ID: 1889762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of anticoagulant mechanism of low molecular weight heparin.
    Hamano S; Nishiyama M; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 Mar; 65(6):801-8. PubMed ID: 1321995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.
    Carter CJ; Kelton JG; Hirsh J; Cerskus A; Santos AV; Gent M
    Blood; 1982 Jun; 59(6):1239-45. PubMed ID: 7082826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.
    Holmer E; Mattsson C; Nilsson S
    Thromb Res; 1982 Mar; 25(6):475-85. PubMed ID: 7112507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of low molecular-weight heparin in hemodialysis patients].
    Schrader J; Rieger J; Müschen H; Stibbe W; Köstering H; Kramer P; Scheler F
    Klin Wochenschr; 1985 Jan; 63(2):49-55. PubMed ID: 3981950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
    Bernat A; Savi P; Lale A; Hoffmann P; Herbert JM
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):573-9. PubMed ID: 10218727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.